Newsroom | Vertex Pharmaceuticals Newsroom
Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis
Press Releases | Vertex Pharmaceuticals Newsroom
Press Releases | Vertex Pharmaceuticals Newsroom
Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
Apr 10, 2024 · Under the terms of the merger agreement, Vertex will acquire Alpine for $65 per share in cash, for a total equity value of approximately $4.9 billion, or approximately $4.6 billion net of estimated cash acquired. A subsidiary of Vertex will commence a cash tender offer to purchase all outstanding shares of Alpine common stock.
Vertex Announces Results From Phase 2 Study of Suzetrigine for …
Dec 19, 2024 · Vertex plans to advance suzetrigine into pivotal development for painful LSR following discussions with regulators on the study design and regulatory package. The company will apply learnings from analysis of the full Phase 2 data set and post-hoc analyses to inform the Phase 3 study design.
Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily …
Dec 20, 2024 · Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis - ALYFTREK ™ is approved for patients 6 years and older with at least one responsive mutation, including 31 additional mutations not responsive to other CFTR modulator therapies -
Vertex Reports Third Quarter 2024 Financial Results | Vertex ...
Sep 30, 2024 · BOSTON--(BUSINESS WIRE)--Nov. 4, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2024, and raised its full-year product revenue guidance to …
Vertex Announces Positive Results From the VX-548 Phase 3 …
Jan 30, 2024 · Vertex’s approach is to selectively inhibit NaV1.8 using small molecules with the objective of creating a new class of medicines that have the potential to provide effective relief of pain without the limitations of opioids, including their addictive potential.
Press Release - Vertex Pharmaceuticals Newsroom
Jul 30, 2024 · BOSTON--(BUSINESS WIRE)--Jul. 30, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submission for suzetrigine, an investigational, oral, selective NaV1.8 pain signal inhibitor to treat moderate-to-severe acute …
Vertex Highlights First Oral Presentation of Phase 3 Clinical Data of ...
Sep 26, 2024 · Vertex will have four poster presentations that include clinical trial and real-world evidence data, three specifically on TRIKAFTA ® and one showing sustained benefits from KALYDECO ®, which is approved for treatment in the youngest ages.
Press Release - Vertex Pharmaceuticals Newsroom
Mar 9, 2023 · Vertex’s first clinical investigational program in T1D, VX-880, is a stem cell-derived, fully differentiated, insulin-producing islet cell replacement therapy used in combination with immunosuppression. Vertex has demonstrated clinical proof-of-concept in the VX-880 program, and the Phase 1/2 clinical study is ongoing in the U.S. and Canada.